133 related articles for article (PubMed ID: 25400413)
1. Effect of methotrexate conjugated PAMAM dendrimers on the viability of MES-SA uterine cancer cells.
Khatri S; Das NG; Das SK
J Pharm Bioallied Sci; 2014 Oct; 6(4):297-302. PubMed ID: 25400413
[TBL] [Abstract][Full Text] [Related]
2. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines.
Gurdag S; Khandare J; Stapels S; Matherly LH; Kannan RM
Bioconjug Chem; 2006; 17(2):275-83. PubMed ID: 16536456
[TBL] [Abstract][Full Text] [Related]
3. Folate Receptor-Targeted Dendrimer-Methotrexate Conjugate for Inflammatory Arthritis.
Qi R; Majoros I; Misra AC; Koch AE; Campbell P; Marotte H; Bergin IL; Cao Z; Goonewardena S; Morry J; Zhang S; Beer M; Makidon P; Kotlyar A; Thomas TP; Baker JR
J Biomed Nanotechnol; 2015 Aug; 11(8):1431-41. PubMed ID: 26295143
[TBL] [Abstract][Full Text] [Related]
4. [PEGylated polyamidoamine dendrimer/methotrexate complex: pharmacokinetics and anti-tumor activity in normal and tumor-bearing rodents].
Kong SY; Tang GT; Pei YY; Jiang YY
Yao Xue Xue Bao; 2009 Jan; 44(1):85-90. PubMed ID: 19350828
[TBL] [Abstract][Full Text] [Related]
5. Molecular heterogeneity analysis of poly(amidoamine) dendrimer-based mono- and multifunctional nanodevices by capillary electrophoresis.
Shi X; Majoros IJ; Patri AK; Bi X; Islam MT; Desai A; Ganser TR; Baker JR
Analyst; 2006 Mar; 131(3):374-81. PubMed ID: 16496045
[TBL] [Abstract][Full Text] [Related]
6. Cellular uptake of glucoheptoamidated poly(amidoamine) PAMAM G3 dendrimer with amide-conjugated biotin, a potential carrier of anticancer drugs.
Uram Ł; Szuster M; Filipowicz A; Zaręba M; Wałajtys-Rode E; Wołowiec S
Bioorg Med Chem; 2017 Jan; 25(2):706-713. PubMed ID: 27919613
[TBL] [Abstract][Full Text] [Related]
7. Photochemical release of methotrexate from folate receptor-targeting PAMAM dendrimer nanoconjugate.
Choi SK; Thomas TP; Li MH; Desai A; Kotlyar A; Baker JR
Photochem Photobiol Sci; 2012 Apr; 11(4):653-60. PubMed ID: 22234658
[TBL] [Abstract][Full Text] [Related]
8. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex.
Jiang YY; Tang GT; Zhang LH; Kong SY; Zhu SJ; Pei YY
J Drug Target; 2010 Jun; 18(5):389-403. PubMed ID: 20055559
[TBL] [Abstract][Full Text] [Related]
9. Preparation and in vitro characterization of pluronic-attached polyamidoamine dendrimers for drug delivery.
Gu Z; Wang M; Fang Q; Zheng H; Wu F; Lin D; Xu Y; Jin Y
Drug Dev Ind Pharm; 2015 May; 41(5):812-8. PubMed ID: 24745851
[TBL] [Abstract][Full Text] [Related]
10. Design considerations for PAMAM dendrimer therapeutics.
Goonewardena SN; Kratz JD; Zong H; Desai AM; Tang S; Emery S; Baker JR; Huang B
Bioorg Med Chem Lett; 2013 May; 23(10):2872-5. PubMed ID: 23583511
[TBL] [Abstract][Full Text] [Related]
11. PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic.
Huang B; Otis J; Joice M; Kotlyar A; Thomas TP
Biomacromolecules; 2014 Mar; 15(3):915-23. PubMed ID: 24392665
[TBL] [Abstract][Full Text] [Related]
12. Bifunctional PAMAM dendrimer conjugates of folic acid and methotrexate with defined ratio.
Zong H; Thomas TP; Lee KH; Desai AM; Li MH; Kotlyar A; Zhang Y; Leroueil PR; Gam JJ; Banaszak Holl MM; Baker JR
Biomacromolecules; 2012 Apr; 13(4):982-91. PubMed ID: 22360561
[TBL] [Abstract][Full Text] [Related]
13. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex.
Patri AK; Kukowska-Latallo JF; Baker JR
Adv Drug Deliv Rev; 2005 Dec; 57(15):2203-14. PubMed ID: 16290254
[TBL] [Abstract][Full Text] [Related]
14. Study of the interactions of PAMAM G3-NH2 and G3-OH dendrimers with 5-fluorouracil in aqueous solutions.
Buczkowski A; Waliszewski D; Urbaniak P; Palecz B
Int J Pharm; 2016 May; 505(1-2):1-13. PubMed ID: 27039147
[TBL] [Abstract][Full Text] [Related]
15. Poly(amidoamine) dendrimer-methotrexate conjugates: the mechanism of interaction with folate binding protein.
van Dongen MA; Rattan R; Silpe J; Dougherty C; Michmerhuizen NL; Van Winkle M; Huang B; Choi SK; Sinniah K; Orr BG; Banaszak Holl MM
Mol Pharm; 2014 Nov; 11(11):4049-58. PubMed ID: 25222480
[TBL] [Abstract][Full Text] [Related]
16. Bone-targeting dendrimer for the delivery of methotrexate and treatment of bone metastasis.
Yamashita S; Katsumi H; Sakane T; Yamamoto A
J Drug Target; 2018 Nov; 26(9):818-828. PubMed ID: 29376757
[TBL] [Abstract][Full Text] [Related]
17. Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport.
Hong S; Bielinska AU; Mecke A; Keszler B; Beals JL; Shi X; Balogh L; Orr BG; Baker JR; Banaszak Holl MM
Bioconjug Chem; 2004; 15(4):774-82. PubMed ID: 15264864
[TBL] [Abstract][Full Text] [Related]
18. Octreotide-conjugated PAMAM for targeted delivery to somatostatin receptors over-expressed tumor cells.
Peng J; Qi X; Chen Y; Ma N; Zhang Z; Xing J; Zhu X; Li Z; Wu Z
J Drug Target; 2014 Jun; 22(5):428-38. PubMed ID: 24437350
[TBL] [Abstract][Full Text] [Related]
19. Tumor cell imaging using the intrinsic emission from PAMAM dendrimer: a case study with HeLa cells.
Biswal BK; Kavitha M; Verma RS; Prasad E
Cytotechnology; 2009 Nov; 61(1-2):17-24. PubMed ID: 19908158
[TBL] [Abstract][Full Text] [Related]
20. Polyvalent saccharide-functionalized generation 3 poly(amidoamine) dendrimer-methotrexate conjugate as a potential anticancer agent.
Zhang Y; Thomas TP; Lee KH; Li M; Zong H; Desai AM; Kotlyar A; Huang B; Holl MM; Baker JR
Bioorg Med Chem; 2011 Apr; 19(8):2557-64. PubMed ID: 21459000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
